Toronto Dominion Bank Has $51,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Share on StockTwits

Toronto Dominion Bank lessened its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 98.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,805 shares of the pharmaceutical company’s stock after selling 194,582 shares during the period. Toronto Dominion Bank’s holdings in Vertex Pharmaceuticals were worth $51,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Commonwealth Equity Services LLC increased its holdings in Vertex Pharmaceuticals by 13.6% in the 1st quarter. Commonwealth Equity Services LLC now owns 19,947 shares of the pharmaceutical company’s stock worth $4,746,000 after purchasing an additional 2,393 shares in the last quarter. First Citizens Bank & Trust Co. increased its stake in shares of Vertex Pharmaceuticals by 54.5% in the second quarter. First Citizens Bank & Trust Co. now owns 13,336 shares of the pharmaceutical company’s stock valued at $3,872,000 after buying an additional 4,706 shares during the period. Chesley Taft & Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 383.7% in the second quarter. Chesley Taft & Associates LLC now owns 9,757 shares of the pharmaceutical company’s stock valued at $2,833,000 after buying an additional 7,740 shares during the period. DNB Asset Management AS increased its stake in shares of Vertex Pharmaceuticals by 19.5% in the second quarter. DNB Asset Management AS now owns 32,160 shares of the pharmaceutical company’s stock valued at $9,336,000 after buying an additional 5,256 shares during the period. Finally, Raymond James Trust N.A. increased its stake in shares of Vertex Pharmaceuticals by 11.7% in the second quarter. Raymond James Trust N.A. now owns 3,963 shares of the pharmaceutical company’s stock valued at $1,151,000 after buying an additional 415 shares during the period. 93.42% of the stock is owned by institutional investors and hedge funds.

In related news, Chairman Jeffrey M. Leiden sold 32,792 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $286.15, for a total transaction of $9,383,430.80. Following the transaction, the chairman now owns 29,252 shares in the company, valued at approximately $8,370,459.80. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Amit Sachdev sold 1,941 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $278.28, for a total value of $540,141.48. Following the transaction, the executive vice president now owns 37,044 shares in the company, valued at approximately $10,308,604.32. The disclosure for this sale can be found here. In the last three months, insiders sold 41,204 shares of company stock valued at $11,836,329. 0.70% of the stock is currently owned by corporate insiders.

Several equities research analysts have recently weighed in on the company. Cowen increased their price target on Vertex Pharmaceuticals from $265.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. Piper Sandler raised their target price on Vertex Pharmaceuticals from $302.00 to $327.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Oppenheimer raised their target price on Vertex Pharmaceuticals from $265.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Credit Suisse Group raised their target price on Vertex Pharmaceuticals from $298.00 to $328.00 and gave the stock an “outperform” rating in a research note on Monday, July 20th. Finally, SunTrust Banks raised their target price on Vertex Pharmaceuticals from $285.00 to $330.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $295.81.

Shares of NASDAQ VRTX traded up $1.47 during midday trading on Thursday, reaching $271.54. The company had a trading volume of 22,225 shares, compared to its average volume of 1,317,611. Vertex Pharmaceuticals Incorporated has a one year low of $165.23 and a one year high of $306.08. The company has a quick ratio of 3.60, a current ratio of 3.72 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average price is $282.80 and its 200-day moving average price is $261.25. The stock has a market cap of $70.67 billion, a PE ratio of 34.02, a price-to-earnings-growth ratio of 1.66 and a beta of 0.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Thursday, July 30th. The pharmaceutical company reported $2.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.86. Vertex Pharmaceuticals had a return on equity of 28.55% and a net margin of 38.51%. The company had revenue of $1.52 billion during the quarter, compared to analyst estimates of $1.41 billion. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 8.2 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Read More: Learning About the VIX – Volatility Index

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply